MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/fonc.2026.1853205

Медицинская библиотека · Frontiers in oncology · 2026

Comparative efficacy and safety of pharmacological treatments for lower-risk myelodysplastic syndromes: a Systematic Review and network meta-analysis.

Zhang Haixia, Hu Jiaqiang, Jiang Yaxi, Deng Lihua, Liu Song

СтатьяСистематический обзорПеревод пока не подготовлен

Аннотация

BACKGROUND

The comparative efficacy of pharmacological treatments for lower-risk myelodysplastic syndromes (LR-MDS) remains uncertain because head-to-head randomised evidence is limited.

METHODS

We performed a systematic review and network meta-analysis of randomised controlled trials evaluating pharmacological treatments for LR-MDS. Outcomes of interest were haematological improvement-erythroid (HI-E), red blood cell transfusion independence (RBC-TI), haematological improvement-platelet (HI-P), and adverse events (AEs).

RESULTS

We included 20 trials (2,877 participants), of which 17 trials (2,670 participants) contributed to connected treatment networks. For HI-E, luspatercept and ESA-based regimens were associated with higher rates. Lenalidomide-containing regimens showed favourable RBC-TI outcomes, including lenalidomide plus ESA, lenalidomide with or without ESA and/or G-CSF, and lenalidomide monotherapy. For HI-P, eltrombopag and romiplostim showed potential benefits. Safety profiles differed across treatments: CC-486 and imetelstat were associated with higher odds of neutropenia and gastrointestinal toxicity, whereas luspatercept was associated with increased fatigue and AEs.

CONCLUSION

Comparative treatment benefit in LR-MDS differs by clinical endpoint. These findings support an individualised, goal-directed treatment approach rather than a single universally superior therapy.

SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/prospero/, identifier CRD420251184384.

Для цитирования: Zhang Haixia, Hu Jiaqiang, Jiang Yaxi, Deng Lihua, Liu Song. Comparative efficacy and safety of pharmacological treatments for lower-risk myelodysplastic syndromes: a Systematic Review and network meta-analysis.. Frontiers in oncology. 2026. DOI: 10.3389/fonc.2026.1853205.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.